Weight loss and permanent discontinuation across obesity treatment-initiation strategies: Bayesian longitudinal network meta-analysis

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Obesity pharmacotherapy strategies differ in maintenance dose, titration and lifestyle support, but existing syntheses largely compare drugs rather than treatment-initiation decisions. We assessed 1-year weight reduction, permanent discontinuation and incremental benefit–discontinuation trade-offs under aligned estimands, while mapping attrition of eligible trial evidence.

Methods

We searched eight databases and two trial registries from inception to October, 2026, for randomised trials (≥12 weeks) of obesity pharmacotherapy initiation in adults with overweight or obesity. Maintenance, withdrawal and switching trials were excluded. Two reviewers independently selected studies, extracted data and assessed bias and certainty. We mapped analytical attrition and used Bayesian longitudinal network meta-analysis to estimate treatment-policy-compatible weight change at 52 weeks, alongside reference networks and analyses of discontinuation, dose escalation, titration, lifestyle support and diabetes-related attenuation. The protocol was prospectively registered with PROSPERO (CRD420261532130).

Findings

We included 180 reports from 178 trials (196 randomisation units; 81 014 participants). Only 78 units met criteria for 1-year assessment; the primary longitudinal model in adults without diabetes incorporated 50 units (including trials reporting 12–24-week interim data), and 45 of 160 target strategies had non-extrapolated 52-week support. The largest placebo-adjusted weight reductions were with retatrutide 12 mg (−19·80 percentage points, 95% CrI −21·81 to −17·78), tirzepatide 15 mg (−16·87, −18·07 to −15·51) and cagrilintide–semaglutide 2·4/2·4 mg (−16·37, −18·10 to −14·70). Only tirzepatide 15 mg and semaglutide 2·4 mg had high-certainty evidence. Thirteen of 32 evaluated strategies significantly increased adverse-event-related permanent discontinuation versus placebo, whereas none significantly increased all-cause discontinuation. Five of 22 adjacent dose steps had ≥0·80 probability of adding >2 percentage points of weight reduction, although discontinuation effects were uncertain or unavailable for some steps. Only eight 1-year titration contrasts and three trials of randomised lifestyle-support increments were identified. Weight reduction in adults with type 2 diabetes was 62% of that without diabetes (ratio 0·62, 95% CI 0·58–0·66).

Interpretation

Only a small fraction of eligible trials directly informs 1-year treatment-initiation decisions. Higher-dose and multi-receptor strategies offer substantial weight reduction, but certainty and discontinuation trade-offs vary. Standardised treatment-policy reporting and randomised evidence on titration and lifestyle support are needed.

Funding

None.

Article activity feed